Fewer than a tenth of individuals eligible to benefit from obesity jabs including Wegovy have access to them, states the World Health Organization as it issues its inaugural advice on the drugs.
Given in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is calling for more widespread and fairer access to these injectable treatments.
Per forecasts, over two billion could be obese by 2030 unless action is taken.
"The latest guidelines recognises that obesity is a long-term condition that can be treated with thorough and continuous support," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are key hurdles to universal availability to the treatments that can aid individuals in losing significant weight, says the organization.
GLP-1 Therapy Supply Crisis
Even under the present best projected scenario, the production of these medications could only cover approximately 100 million people – under 10% of the global need, per the WHO.
The guideline urges countries and companies to widen availability, through strategies like licensing agreements.
The intellectual property rights on the active ingredient – the primary component of Novo Nordisk's Wegovy – is due to expire in a number of countries in 2026.
How Obesity Injections Function
GLP-1 drugs imitate a natural hormone to delay gastric emptying, curb appetite and boost satiety so people consume fewer calories.
Individuals commonly begin shedding pounds in the initial weeks of commencing the once-weekly jabs.
Studies indicates people may regain a significant portion after a year of discontinuing the medication, because their typical hunger return.
To be overweight or obese raises your likelihood for developing medical conditions, such as type 2 diabetes, heart disease, stroke, and certain malignancies.
Excess weight concerns people in countries worldwide and was associated with 3.7 million deaths worldwide in 2024, per the WHO.
